GAITHERSBURG, Md.--(BUSINESS WIRE)--Gene Logic Inc. (NASDAQ: GLGC) announced today recognition of a collaboration milestone, triggered by the filing of a patent application for a new use of an existing Pfizer drug candidate to treat solid tumors. The new use for the unapproved drug candidate was discovered by Gene Logic‘s Drug Repositioning Division.
